Computerized Cognition Testing in Participants With Mild Alzheimer's Disease (AD) Treated With Donepezil (MK-0000-318)

Model scores of the 29,894 trials active now.

Model score 23% for any early termination, 3% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 19% of the time (731 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2016-07-13. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: has historyto determinescreeningevidenceplacebo
  Phrases that lowered it: participantsclinical trialasthmaparticipatedto visit
• Sponsor's past termination rate: 17.2% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Minimum age: 55 (raises risk) · Who can join
• Sponsor's past trials: 1013 (raises risk) · Sponsor's track record
• Primary purpose: diagnostic (lowers risk) · Design
• Phase: 2 (raises risk) · Design
• Design: parallel (raises risk) · Design
• Drug's FAERS reports with a death: 14.6% (lowers risk) · Drug's FDA history
• Maximum age: 85 (raises risk) · Who can join
• Blinding: triple (raises risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Disease area, neurology: Yes (raises risk) · Disease area
• Disease area, psychiatry: Yes (raises risk) · Disease area
• Disease area, cancer: No (lowers risk) · Disease area
• Keywords listed: 0 (raises risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Responsible party: sponsor (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 139 (lowers risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study to Test the Performance of the CogState Computerized Neuropsychological Battery in Patients With Alzheimer's Disease (0000-086)(COMPLETED) NCT00777608 · started 2008 · scored riskier than 40% of active trials completed
• Cognition Platform Study in Participants at Risk for Alzheimer's Disease (AD) (MK-0000-413) NCT04730635 · started 2021 · scored riskier than 93% of active trials completed
• Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease NCT03486938 · started 2018 · scored riskier than 92% of active trials completed
• AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext NCT01741194 · started 2013 · scored riskier than 58% of active trials completed
• A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu) NCT02727699 · started 2017 · scored riskier than 81% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.